Physician profile
Michael D Brown
NPI 1760825426
$1,525.50
in general payments reported to CMS, 2019-2025
21 companies · $67.36 in 2025
The $67.36 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $274 · 2021: $349 · 2022: $142 · 2023: $105 · 2024: $65.58 · 2025: $67.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $300.31 | 2019-2022 | |
| Neos Therapeutics, LP | $211.26 | 2019-2023 | Cotempla Xr-Odt |
| Tris Pharma INC | $201.26 | 2019-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $133.59 | 2019-2024 | Bexsero |
| Sobi, INC | $129.99 | 2019-2021 | |
| Corium, LLC | $103.43 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $102.08 | 2019-2022 | |
| Pfizer INC. | $72.98 | 2019-2025 | |
| Cranial Technologies, INC | $49.15 | 2019-2021 | |
| Shire North American Group INC | $27.50 | 2019 | |
| Kaleo, INC. | $25.46 | 2019-2021 | |
| Adlon Therapeutics L.P. | $23.81 | 2020-2021 | |
| Sanofi Pasteur INC. | $20.95 | 2023 | |
| Alk-Abello, INC | $19.17 | 2024 | Odactra, Ragwitek, Grastek |
| Noven Therapeutics, LLC | $16.88 | 2025 | Xelstrym |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.19 | 2025 | Rotateq, Gardasil 9 |
| Genentech USA, INC. | $15.99 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.91 | 2023 | |
| Seqirus USA INC | $13.72 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.